These data demonstrate that inhibition of PI3Kδ and BTK signaling pathways significantly impacts downstream signaling pathways as measured by p-S6RP and c-MYC, translating into additive antitumor efficacy in the TMD8 model of ABC DLBCL. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.